Description: Taribavirin (ICN-3142,Ribamidine, AVS-206, KD-024, Viramidine), a prodrug of Ribavirin,is an inosine monophosphate dehydrogenase inhibitor with antiviral activity against a wide range of RNA/DNA viruses, especially the hepatitis C virus and influenza virus. Taribavirin is a Ribavirin prodrug designed to be enriched within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia. Taribavirin has better liver-targeting capability than ribavirin, and has a shorter life in the body due to less penetration and storage in red blood cells.
References:
[1]. Taribavirin and 5-Fluorouracil-Loaded Pegylated-Lipid Nanoparticle Synthesis, p38 Docking, and Antiproliferative Effects on MCF-7 Breast Cancer. Pharm Res. 2018 Feb 27;35(4):76.
[2]. Taribavirin in the treatment of hepatitis C. Expert Opin Investig Drugs. 2011 Oct;20(10):1435-43.
Related CAS #: 40372-00-7 (HCl) 119567-79-2 (free base)